Omicron: a drug developer’s perspective

Fang Flora Fang; Pei Yong Shi

doi:10.1080/22221751.2021.2023330

Omicron: a drug developer’s perspective

Fang Flora Fang, Pei Yong Shi

Biochemistry & Molecular Biology

Research output: Contribution to journal › Comment/debate › peer-review

26 Scopus citations

Abstract

We performed an annotation of 35 mutations in the spike protein of the SARS-CoV-2 Omicron variant. Our analysis of the mutations indicates that Omicron has gained prominent immune evasion and potential for enhanced transmissibility. Previous modeling study has revealed that continued evolution in both immune evasion and enhanced transmissibility by SARS-CoV-2 would compromise vaccines as tools for the pandemic control. To combat the future variants of SARS-CoV-2, the world needs novel antiviral drugs that are effective at curb viral spreading without introducing additional selective pressure towards resistant variants.

Original language	English (US)
Pages (from-to)	208-211
Number of pages	4
Journal	Emerging Microbes and Infections
Volume	11
Issue number	1
DOIs	https://doi.org/10.1080/22221751.2021.2023330
State	Published - Dec 31 2022

Keywords

COVID19
COVID19drugs
COVID19vaccines
Omicron variants
SARS-CoV-2

ASJC Scopus subject areas

Drug Discovery
Infectious Diseases
Epidemiology
Virology
Parasitology
Microbiology
Immunology

Access to Document

10.1080/22221751.2021.2023330

Cite this

@article{912504edb93d4bb889c7eb2f60fa112f,

title = "Omicron: a drug developer{\textquoteright}s perspective",

abstract = "We performed an annotation of 35 mutations in the spike protein of the SARS-CoV-2 Omicron variant. Our analysis of the mutations indicates that Omicron has gained prominent immune evasion and potential for enhanced transmissibility. Previous modeling study has revealed that continued evolution in both immune evasion and enhanced transmissibility by SARS-CoV-2 would compromise vaccines as tools for the pandemic control. To combat the future variants of SARS-CoV-2, the world needs novel antiviral drugs that are effective at curb viral spreading without introducing additional selective pressure towards resistant variants.",

keywords = "COVID19, COVID19drugs, COVID19vaccines, Omicron variants, SARS-CoV-2",

author = "Fang, {Fang Flora} and Shi, {Pei Yong}",

note = "Publisher Copyright: {\textcopyright} 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.",

year = "2022",

month = dec,

day = "31",

doi = "10.1080/22221751.2021.2023330",

language = "English (US)",

volume = "11",

pages = "208--211",

journal = "Emerging Microbes and Infections",

issn = "2222-1751",

publisher = "Taylor and Francis Ltd.",

number = "1",

}

TY - JOUR

T1 - Omicron

T2 - a drug developer’s perspective

AU - Fang, Fang Flora

AU - Shi, Pei Yong

PY - 2022/12/31

Y1 - 2022/12/31

N2 - We performed an annotation of 35 mutations in the spike protein of the SARS-CoV-2 Omicron variant. Our analysis of the mutations indicates that Omicron has gained prominent immune evasion and potential for enhanced transmissibility. Previous modeling study has revealed that continued evolution in both immune evasion and enhanced transmissibility by SARS-CoV-2 would compromise vaccines as tools for the pandemic control. To combat the future variants of SARS-CoV-2, the world needs novel antiviral drugs that are effective at curb viral spreading without introducing additional selective pressure towards resistant variants.

AB - We performed an annotation of 35 mutations in the spike protein of the SARS-CoV-2 Omicron variant. Our analysis of the mutations indicates that Omicron has gained prominent immune evasion and potential for enhanced transmissibility. Previous modeling study has revealed that continued evolution in both immune evasion and enhanced transmissibility by SARS-CoV-2 would compromise vaccines as tools for the pandemic control. To combat the future variants of SARS-CoV-2, the world needs novel antiviral drugs that are effective at curb viral spreading without introducing additional selective pressure towards resistant variants.

KW - COVID19

KW - COVID19drugs

KW - COVID19vaccines

KW - Omicron variants

KW - SARS-CoV-2

UR - http://www.scopus.com/inward/record.url?scp=85123166334&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85123166334&partnerID=8YFLogxK

U2 - 10.1080/22221751.2021.2023330

DO - 10.1080/22221751.2021.2023330

M3 - Comment/debate

C2 - 34951568

AN - SCOPUS:85123166334

SN - 2222-1751

VL - 11

SP - 208

EP - 211

JO - Emerging Microbes and Infections

JF - Emerging Microbes and Infections

IS - 1

ER -

Omicron: a drug developer’s perspective

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this